Poolbeg expects first data for CRS drug in the summer

Changing Faces: Board of Directors and Advisory Boards, March 2026

ESMO25: Transforming the cancer immunotherapy field, with Poolbeg’s Liam Tremble

Political uncertainties, tariffs, funding crunch? LSX World Congress upbeat despite the times

The opportunities and challenges facing rare disease therapies developers

Changing Faces: Pharma and biotech hires from February 2024